ANTIBODY COCKTAILS MARKET ANALYSIS

An antibody is a protein made by immune cells that is of or specific shape and size so that it can attach itself to a specific point on a particular foreign substance, such as a virus or bacteria. By attaching, the antibody can potentially prevent these invaders from causing an infection. An antibody cocktail is a therapy which is a cocktail of two antibodies, which are basically the proteins that body generates to defend or protect itself against any disease. For example, monoclonal antibody cocktail of the antibodies Casirivimab and Imdevmab has proven to show positive results for recovering faster from COVID-19 infection.

The global antibody cocktails market was valued at US$ 2,113.5 million in 2021 and is expected to exhibit a CAGR of 10.9% during the forecast period (2021-2028).

Figure 1. Global Antibody Cocktails Market Share (%) in Terms of Value, by Type, 2021

To learn more about this report, request a free sample copy

Increasing prevalence of infectious diseases is expected to drive the market growth during the forecast period.

The increasing prevalence of various infectious diseases such as COVID-19 is expected to drive the market growth during the forecast period. For instance, according to the World Health Organization Coronavirus (COVID-19) dashboard, over 396,558,014 cases and 5,745,032 deaths due to coronavirus (COVID-19) were reported as of February 8, 2022, across the globe.

Figure 2. Global Antibody Cocktails Market Share (%), by Distribution Channel, 2021

To learn more about this report, request a free sample copy

Increasing product approvals by the regulatory bodies is expected to drive market growth during the forecast period.

The increasing product approvals for the antibody cocktails therapy by the regulatory bodies is expected to drive growth of the global antibody cocktails market over the forecast period. For instance, in Decemeber 2021, AstraZeneca,  a multinational pharmaceutical and biotechnology company received the U.S. Food and Drug Administration emergency use authorization (EUA) for its antibody cocktail Evusheld (tixagevimab co-packaged with cilgavimab and administered together) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and pediatric individuals.

Global Antibody Cocktails Market – Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions.

However, the pandemic has positively impacted the global antibody cocktails market, owing to the increasing research and development activities by the key players to develop antibody cocktails and lower the risk of hospitalization in the case of severe COVID-19 infected patients. For instance, in July 2021, the Brihanmumbai Municipal Corporation (BMC) said that a preliminary experiment of a cocktail of two antibody drugs- Casirvimab and Imdevimab, for the treatment of COVID-19, has been successful. The BMC said that the number of patients requiring oxygen after this cocktail medication was only 0.5% and the mortality rate was reduced by 70%. Earlier, the requirement for hospitalization was 13 to 14 days, which was reduced to 5 to 6 days after administering this antibody cocktail therapy.

Global Antibody Cocktails Market: Restraint

The major factors that hinder growth of the global antibody cocktails market include the high cost of the drugs and stringent government regulations for product approval. For instance, the antibody cocktail therapy REGEN-COV (Casrivimab and Imdevimab) developed by Regeneron Pharmaceuticals Inc., a biotechnology company,  is priced at US$ 2,100 per dose in the U.S., US$ 2,000 per dose in Germany and US$ 820 per dose in India.

Key Players

Major players operating in the global antibody cocktails market include Cipla Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., Zydus Cadila, AstraZeneca, Aridis Pharmaceuticals Inc., Immunome Inc., Celltrion Healthcare Co.,Ltd., and Eli Lilly and Company.